PCN21 FIRST-LINE BEVACIZUMAB-BASED THERAPY VERSUS PEMETREXED CISPLATIN FOR THE TREATMENT OF ADVANCED ADENOCARCINOMA NONSQUAMOUS NON-SMALL CELL LUNG CANCER- INDIRECT COMPARISON APPLYING REAL-LIFE OUTCOMES
Nov 1, 2010, 00:00
10.1016/S1098-3015(11)71918-0
https://www.valueinhealthjournal.com/article/S1098-3015(11)71918-0/fulltext
Title :
PCN21 FIRST-LINE BEVACIZUMAB-BASED THERAPY VERSUS PEMETREXED CISPLATIN FOR THE TREATMENT OF ADVANCED ADENOCARCINOMA NONSQUAMOUS NON-SMALL CELL LUNG CANCER- INDIRECT COMPARISON APPLYING REAL-LIFE OUTCOMES
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)71918-0&doi=10.1016/S1098-3015(11)71918-0
First page :
A255
Section Title :
RESEARCH POSTER ABSTRACTS
Open access? :
No
Section Order :
81